Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baseline characteristics of European and non-European adult patients with attention deficit hyperactivity disorder participating in a placebo-controlled, randomized treatment study with atomoxetine.
Upadhyaya H, Adler LA, Casas M, Kutzelnigg A, Williams D, Tanaka Y, Arsenault J, Escobar R, Allen AJ. Upadhyaya H, et al. Among authors: escobar r. Child Adolesc Psychiatry Ment Health. 2013 May 6;7(1):14. doi: 10.1186/1753-2000-7-14. Child Adolesc Psychiatry Ment Health. 2013. PMID: 23648011 Free PMC article.
Predictors of relapse or maintenance of response in pediatric and adult patients with attention-deficit/hyperactivity disorder following discontinuation of long-term treatment with atomoxetine.
Thome J, Dittmann RW, Greenhill LL, Lipsius S, Tanaka Y, Bushe C, Escobar R, Heinloth AN, Upadhyaya H. Thome J, et al. Among authors: escobar r. Atten Defic Hyperact Disord. 2017 Dec;9(4):219-229. doi: 10.1007/s12402-017-0227-8. Epub 2017 May 5. Atten Defic Hyperact Disord. 2017. PMID: 28477289
Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials.
Wehmeier PM, Schacht A, Escobar R, Savill N, Harpin V. Wehmeier PM, et al. Among authors: escobar r. Child Adolesc Psychiatry Ment Health. 2010 Dec 6;4:30. doi: 10.1186/1753-2000-4-30. Child Adolesc Psychiatry Ment Health. 2010. PMID: 21134277 Free PMC article.
Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine.
Montoya A, Escobar R, García-Polavieja MJ, Lachno DR, Alda JÁ, Artigas J, Cardo E, García M, Gastaminza X, Gilaberte I. Montoya A, et al. Among authors: escobar r. J Child Neurol. 2011 Jan;26(1):31-6. doi: 10.1177/0883073810371981. Epub 2010 Jun 4. J Child Neurol. 2011. PMID: 20525942 Clinical Trial.
176 results